Calcitonin for metastatic bone pain

Martinez‐Zapata, Maria José; Figuls, Marta Roqué i; Català, E.; Roman, Yuani M.; Alonso‐Coello, Pablo

doi:10.1002/14651858.cd003223.pub2

Cited by 42 publications

(17 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…279 From the two studies examined, the first showed a nonsignificant effect of calcitonin in the number of patients with total pain reduction, and the second provided no evidence of minimized analgesics consumption due to hormone administration.…”

Section: Calcitoninmentioning

confidence: 99%

Pharmacological Treatment of Neuropathic Cancer Pain: A Comprehensive Review of the Current Literature

et al. 2011

View full text Add to dashboard Cite

Neuropathic cancer pain (NCP), commonly encountered in clinical practice, may be cancer-related, namely resulting from nervous system tumor invasion, surgical nerve damage during tumor removal, radiation-induced nerve damage and chemotherapy-related neuropathy, or may be of benign origin, unrelated to cancer. A neuropathic component is evident in about 1/3 of cancer pain cases.Although from a pathophysiological perspective NCP may differ from chronic neuropathic pain (NP), such as noncancer-related pain, clinical practice, and limited publications have shown that these two pain entities may share some treatment modalities. For example, co-analgesics have been well integrated into cancer pain-management strategies and are often used as First-Line options for the treatment of NCP. These drugs, including antidepressants and anticonvulsants, are recommended by evidence-based guidelines, whereas, others such as lidocaine patch 5%, are supported by randomized, controlled, clinical data and are included in guidelines for restricted conditions treatment. The vast majority of these drugs have already been proven useful in the management of benign NP syndromes. Treatment decisions for patients with NP can be difficult. The intrinsic difficulties in performing randomized controlled trials in cancer pain have traditionally justified the acceptance of drugs already known to be effective in benign NP for the management of malignant NP, despite the lack of relevant high quality data. Interest in NCP mechanisms and pharmacotherapy has increased, resulting in significant mechanism-based treatment advances for the future. In this comprehensive review, we present the latest knowledge regarding NCP pharmacological management. n INTRODUCTIONFollowing EFIC's (European Federation of IASP Chapters) declaration in 2001, pain is not a symptom but a disease in its own right, necessitating appropriate treatment. The word pain usually refers to a discrete sensory experience, triggered by an identifiable set of ''painful'' stimuli, acting on a unique or stable ''pain'' pathway and eliciting an invariant sensation. However, pain, and particularly neuropathic pain (NP) can also exist as a diverse group of complex phenomena of unpleasant and distressing nature. NP encloses numerous complicated neurobiologic constituents and reflects potentially dynamic mechanisms, interacting at multiple neuraxial sites. 1Modern neurobiological techniques have led to tremendous progress in the exploration of pain pathogenetic mechanisms. [2][3][4] Research indicates that pain can be produced in multiple ways, at different locations, co-existing between and across various pathological conditions. 5,6 Novel therapeutic targets have been discovered and are used by the pharmaceutical industry for the construction of highly specific molecules, acting as potential innovative analgesics. Recent targets' application, specific to precise NP mechanisms, will very soon enable treatment to be focused at particular mechanisms, introducing a mechanism-based therap...

show abstract

Section: Calcitoninmentioning

confidence: 99%

Pharmacological Treatment of Neuropathic Cancer Pain: A Comprehensive Review of the Current Literature

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Does not work for chronic metastatic bone pain 39 Corticosteroids in addition to other pain drugs Methylprednisolone 32-mg/d did not improve pain compared with placebo in patients with cancer but did improve fatigue, nausea, and well-being. 40 Tables 3 and 4.…”

Section: The Second Step: Management Of the Painmentioning

confidence: 92%

Cancer Pain Management

Smith

Saiki

2015

Mayo Clinic Proceedings

View full text Add to dashboard Cite

Safe, effective, and evidence-based management of cancer-related pain is a cornerstone of comprehensive cancer care. Despite increasing interest in and efforts to improve its management, pain remains poorly controlled in nearly half of all patients with cancer, with little change in the past 20 years. Limited training in pain assessment and management, overestimation of providers' own skills to treat pain, and failure to refer patients to pain specialists can result in suboptimal pain management with devastating effects on quality of life, physical functioning, and increased psychological distress. From a thorough assessment of cancer-related pain to appropriate treatments that may include opiates, adjuvant medications, nerve blocks, and nondrug interventions, this article is intended as a brief overview of the mechanisms and types of pain as well as a review of current, new, and promising approaches to its management.

show abstract

“…67 CT was used, and abused, as an analgesic treatment of painful conditions such as osteoporosis, 68 phantom limb pain, 69 diabetic neuropathy, 70 complex regional pain syndrome, 71 migraine, 72 and malignancies. 73 According to studies in different fields, CT has multisystem binding sites including plasma membranes, bone, cultured human lymphocytes, malignant cells, and CNS neurons. The receptors for calcitonin have been found in the thalamus, periaqueductal grey, nucleus gigantocellularis, and raphe nucleus of the mouse brain where serotonergic neurons are located.…”

Section: Calcitoninmentioning

confidence: 99%

Hormones in pain modulation and their clinical implications for pain control: a critical review

Chen¹,

Zhang²,

Wang³

2016

View full text Add to dashboard Cite

Recently, more and more studies have found that pain generation, transmission and modulation are under hormonal regulation. Indeed, hormonal dysregulation is a common component of chronic pain syndromes. Studies have attempted to determine whether the relationship between the pain and its perception and hormones is a causative relationship and how these processes interrelate. This review summarizes and analyzes the current experimental data and provides an overview of the studies addressing these questions. The relationship between pain perception and endocrine effects suggests that hormones can be used as important biomarkers of chronic pain syndromes and/or be developed into therapeutic agents in the fight against pain.

show abstract

Calcitonin for metastatic bone pain

Cited by 42 publications

References 36 publications

Pharmacological Treatment of Neuropathic Cancer Pain: A Comprehensive Review of the Current Literature

Pharmacological Treatment of Neuropathic Cancer Pain: A Comprehensive Review of the Current Literature

Cancer Pain Management

Hormones in pain modulation and their clinical implications for pain control: a critical review

Contact Info

Product

Resources

About